Hims & Hers and the end of GLP-1 compounding It was inevitable The New Yorker dubbed 2023 as the year of Ozempic. It wasnt the year that the drug was invented or first given to patients, but it was the year that it exploded into the public consciousness
The decision allows the FTC to proceed with its case against pharmacy middlemen
GLP-1 Weight Loss Medications: The Good, the Bad, and the Ugly And What Theyre Really Doing to Your Muscle, Metabolism, and Long-Term Results December 19, 2025 GLP-1 Weight Loss Medications: The Good, the Bad, and the Ugly And What Theyre Really Doing to Your Muscle, Metabolism, and Long-Term Results Photo Credit: Shutterstock GLP-1 weight loss medications such as Ozempic, Wegovy, Mounjaro, and Zepbound have exploded in popularity over the last few years
BMI Standards (Commonly Used Criteria): For weight management purposes, GLP-1 medications are typically considered for individuals with: BMI of 30 or higher (obesity), OR BMI of 27 or higher with at least one weight-related comorbidity (high blood pressure, type 2 diabetes, high cholesterol, sleep apnea, etc.) These are general clinical guidelines used in FDA-approved product labeling and may inform provider decisions
H.LapatoA
